The State Medical Security Administration recently reported the situation of pharmaceutical enterprises rated as "particularly serious" and "serious" dishonesty in various provinces from April 1 to June 30 this year. Yunnan Tongfeng Pharmaceutical Co., Ltd. and Ningxia minning Pharmaceutical Co., Ltd. have been investigated for criminal responsibility by the local people's court for giving rebates or illegitimate interests to relevant personnel of the hospital. According to the discretionary benchmark for pharmaceutical price and bidding credit rating (version 2020), the two enterprises were rated as "serious" dishonesty, which means that they lost the opportunity to enter the centralized procurement market for a long time. This is the second notification of such problems by the national medical insurance bureau this year. Previously, Sichuan beijukang Medical Equipment Co., Ltd., Sichuan Sifeng Pharmaceutical Co., Ltd. and Sichuan Pharmaceutical Group Shengtong Pharmaceutical Co., Ltd. were rated as "particularly serious" dishonesty. In the past, pharmaceutical representatives of pharmaceutical enterprises shuttled among medical institutions, allowing hospitals to increase their product purchases and doctors to open more medicines of their companies by giving rebates, which was called "sales with money". Sales with money has always been a stubborn disease in the pharmaceutical industry, which not only leads to the rapid growth of medical expenses and the loss of medical insurance funds, but also induces excessive medical treatment, damages the health rights and interests of the masses, and increases the burden of medical treatment for the masses. According to the statistics of publicly available court judgment documents, from 2016 to 2019, more than half of the top 100 pharmaceutical enterprises in China were verified to have given or indirectly given rebates, of which the most frequent enterprise was involved in more than 20 cases in three years, and the rebate amount in a single case exceeded 20 million yuan. During that period, the average sales expense rate of listed pharmaceutical companies exceeded 30%. It can be said that sales with gold distorts the business environment and industry ecology, and weakens the industry's innovation momentum. In 2020, the national medical insurance bureau established a credit evaluation system for medical prices and bidding and procurement, relying on a centralized procurement platform and linking buyers and sellers with trustworthy commitments, guiding or requiring medical institutions to purchase medical products from honest enterprises, and reducing or suspending the purchase of medical products from dishonest enterprises. Over the past few years, the National Medical Insurance Bureau has taken appropriate measures to deal with dishonest pharmaceutical enterprises that have given rebates and monopolized price increases, which has promoted the reasonable return of pharmaceutical product prices and safeguarded the vital interests of the people. Since the implementation of the system, the phenomenon of sales with gold has decreased significantly. At the national level, the number of enterprises notified has not exceeded 20, which verifies the effectiveness of the system from the side. More and more enterprises realize that the marketing model of sales with money may get a small share, but it loses the national market, and the gains outweigh the losses. We should further sort out the regions and enterprises where gold sales are currently prone to occur. On the one hand, we should strengthen publicity and education to let more enterprises and medical institutions know the interests and prevent the occurrence of gold sales. On the other hand, in recent years, the way of selling with gold has become more and more secretive, so it is necessary to strengthen supervision, increase comprehensive punishment, and leave no room for its continued existence. To continuously improve the quality of medical care for the masses and reduce the burden of medical expenses for the masses, we need to maximize the effectiveness of the limited funds. To eradicate the stubborn disease of selling with money, we must adhere to systematic, comprehensive and source management, and maintain the safe, stable and efficient operation of medical insurance funds